DIAMEDICA THERAPEUTICS INC. overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President & Chief Executive Officer, will participate at the 32 nd Annual ROTH Conference The conference will be held from March 15-17, 2020 at The Ritz Carlton, Laguna Niguel, California. Mr. Pauls will also participate in a panel titled “Great Oaks Come from Little Acorns in NASH, CVD and Chronic Kidney Disease.” The panel will take place on Tuesday, March 17 th at 10:00am Pacific Time. Management will be available...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Phase II clinical trial protocol for the treatment of Chronic Kidney Disease (CKD). The Phase II trial is designed to assess the safety and efficacy of DM199 in the treatment of CKD in two cohorts: patients with CKD caused by IgA nephropathy (IgAN) and hypertensive African American patients with CKD. DiaMedica intends to initiate participant enrollment in the...

MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3 rd Annual Best Ideas Growth (BIG3) Conference on Thursday, September 12th, 2019, at the Parker New York in New York City. DiaMedica’s President and Chief Executive Officer, Rick Pauls, is scheduled to meet with investors on Thursday, September 12th, with one-on-one meetings to be held throughout the day. About the BIG3...

MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor Conference in Minneapolis, Minnesota. Rick Pauls, President and CEO of DiaMedica Therapeutics will host one-on-one institutional investor meetings throughout the day at the event. Dougherty & Co. Institutional Investor Conference Date: Thursday, September 5, 2019 Location: Millennium Hotel (1313 Nicollet Mall,...

Phase Ib study of DM199 in Chronic Kidney Disease enrollment complete Encouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin (UACR) Phase II CKD protocol submitted, trial initiation expected H2 2019 with interim analysis Q1 2020 DiaMedica regains global rights to DM199 in acute ischemic stroke as a result of its termination of Chinese license agreement Conference call with management tomorrow, August 14, 2019 at 7am CT MINNEAPOLIS, Aug. 13, 2019...

MINNEAPOLIS, Aug. 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President and CEO, will be presenting at the 2019 Intellisight Conference, Wednesday, August 14 th at 9:00 am Central Time at University of St. Thomas in Minneapolis, Minnesota. About Intellisight Intellisight is a 2-day conference sponsored by the University of St. Thomas – School of Law for institutional investors to meet with leadership teams from numerous companies,...

MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on Tuesday, August 13 th . DiaMedica will host a live conference call on Wednesday, August 14 th at 7:00am Central Time to discuss its business update and financial results. Conference Call details: Date: Wednesday, August 14, 2019 Time: 7:00 AM CT / 8:00 AM ET Web access:...

Favorable DM199 safety profile across tested doses Pharmacodynamic results helped identify dose range for Phase II studies Encouraging early signals in mechanism biomarkers (NO and PGE 2 ), Kidney function (eGFR) and urine albumin (UACR) Phase II trial initiation expected 2H19 with interim analysis Q4 2019 – Q1 2020 Company to host conference call and webcast on June 20, 2019 at 7:00 a.m. CT MINNEAPOLIS, June 19, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a...